Bionest

Palforzia Benefit in Peanut Allergy Supported by New Data, While FDA Rejects Viaskin Peanut

The first commercial patients for peanut allergy oral therapy Palforzia have started treatment. How will its patch competitor fare?

Bionest

The Search for COVID-19 Biomarkers

There is an urgent need for effective biomarkers to help classify COVID-19 patients based on risk, so that aggressive monitoring and appropriate therapy can be promptly directed to those more likely to get more severe illness.

Bionest

Precision Medicine: Going Beyond Oncology

What has made precision medicine so successful in oncology? What will be needed to advance the field to new areas of application, such as neurology, immunology and women's health?

Bionest

Urgent Race to a Coronavirus Vaccine and New Treatments

As the COVID-19 pandemic continues to rage across the world, companies and national interests are racing to develop and secure access to SARS-CoV-2 vaccines and treatments. Over 180 vaccines are in various stages of development, with a handful having entered Phase 3 testing.

Bionest

COVID-19 and Mental Health

As the coronavirus pandemic continues, a different set of serious health problems has been exacerbated: anxiety, depression, substance abuse and domestic violence.

Bionest

New Efforts Aimed at Increasing Generics Availability, Lowering Prices

Why have prices for certain generic drugs risen? And what is being done to increase availability while keeping costs in check?

Bionest

ASCO 2020: Part 2

In our second ASCO highlights post, we discuss the promising potential of liquid biopsy and comprehensive genotyping in precision oncology, and new indications for Keytruda.

Bionest

ASCO 2020: Part 1

In our first of two ASCO 2020 posts, we discuss clinical data from an off-the-shelf CAR-T therapy, and look at how real-world evidence can be used to help physicians improve outcomes for their cancer patients in ways beyond cancer treatment itself.

Bionest

Funding Environment During COVID-19 Pandemic Sees Both Challenges and Bright Spots

While some pharma and biotech companies are struggling during the COVID-19 pandemic, others are thriving thanks to government grants, joint research initiatives and venture capital.